Showing results (951-960 of 962) with videos related to
Sort By:
Pageof 97
Cell Chemical Biology|March 21, 2020
A Preclinical Candidate Targeting Mycobacterium tuberculosis KasADaigo Inoyama, Divya Awasthi, Glenn C Capodagli, et al.Frontiers in Endocrinology|April 24, 2023
Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trialZhijie Dai, Ronghua Zhu, Zhifeng Sheng, et al.Nature Communications|May 8, 2026
Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2)Weiping Jia, Fei Gao, Jingyi Lu, et al.Nucleic Acids Research|December 1, 2021
miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactionsHsi-Yuan Huang, Yang-Chi-Dung Lin, Shidong Cui, et al.Brain Stimulation|October 14, 2019
Transcranial direct current stimulation reduces seizure frequency in patients with refractory focal epilepsy: A randomized, double-blind, sham-controlled, and three-arm parallel multicenter studyDongju Yang, Qun Wang, Cuiping Xu, et al.Research Square|August 16, 2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.Nature Cancer|February 27, 2025
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.Journal of Orthopaedic Translation|May 25, 2026
Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III studyJiemei Gu, Aijun Chao, Yanan Huo, et al.Science Bulletin|December 22, 2022
Quantum computational advantage via 60-qubit 24-cycle random circuit samplingQingling Zhu, Sirui Cao, Fusheng Chen, et al.Physical Review Letters|November 12, 2021
Strong Quantum Computational Advantage Using a Superconducting Quantum ProcessorYulin Wu, Wan-Su Bao, Sirui Cao, et al.Pageof 97